Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

Jul 07, 2020
|
staff reporter

NEW YORK ─ The US Food and Drug Administration on Monday issued a warning letter to clinical laboratory staff and healthcare providers to alert them about an increased risk of false-positive results from Becton Dickinson's BD SARS-CoV-2 reagents for its BD Max System test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

  2. Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

  3. Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

  4. Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.